Delivery Order SPE2DR25D2206-SPE2DR26F9LF0
Award Date 1/14/26
Potential Completion Date 1/15/26
Potential Value $5.3K
Federal Agency
Awardee
Ultimate Awardee
PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Defense Logistics Agency awarded a delivery order valued at $2,875.81 to AmerisourceBergen Drug Corp for UBRELVY 100 mg tablets (100 unit dose packages of 10 tablets each) on September 5, 2025, with an ultimate completion date of September 8, 2025. This firm fixed-price delivery order represents a non-competitive set-aside purchase and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. UBRELVY (ubrogepant) is a calcitonin gene-related peptide...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,463.95 to AmerisourceBergen Drug Corp for UBRELVY 100 mg tablets (16-unit dose packages) on January 6, 2026, with an ultimate completion date of January 7, 2026. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. UBRELVY (ubrogepant) is an acute migraine treatment, reflecting the pharmaceutical supply...
- The Defense Logistics Agency awarded a $5,909.37 delivery order to AmerisourceBergen Drug Corp for UBRELVY 100 mg tablets (unit dose, 10 count packages) on August 12, 2025, with an ultimate completion date of August 13, 2025. This firm fixed-price contract represents a non-competitive, non-set-aside award and will be performed at the vendor's corporate office in Conshohocken, Pennsylvania. UBRELVY (ubrogepant) is an acute migraine treatment medication, reflecting the Defense Logistics Agency's...
- The Defense Logistics Agency awarded a delivery order valued at $1,804.46 to AmerisourceBergen Drug Corp for the supply of UBRELVY (ubrogepant) 100 mg tablets in unit dose packaging, with an ultimate completion date of December 10, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the contractor's Conshohocken, Pennsylvania location. UBRELVY is a calcitonin gene-related peptide receptor antagonist used for the acute...
- The Defense Logistics Agency awarded a $16,240.76 firm fixed-price delivery order to AmerisourceBergen Drug Corp for UBRELVY (ubrogepant) 100 mg tablets in unit dose packaging on November 4, 2025, with completion scheduled for November 5, 2025. This contract represents a competitive award with no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. UBRELVY is an FDA-approved acute migraine treatment, reflecting the Defense...
- The Defense Logistics Agency awarded a $9,639.92 delivery order to AmerisourceBergen Drug Corp for UBRELVY 100 mg tablets (unit dose, 10s) on September 16, 2025, with an ultimate completion date of September 17, 2025. This competitively awarded, firm fixed-price contract involves no set-aside designation and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. UBRELVY (ubrogepant) is a calcitonin gene-related peptide receptor antagonist used for acute...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for UBRELVY (ubrogepant) 100 mg tablets in unit dose packaging of 10 tablets, with a ceiling value of $1,937.86. The award, issued on September 3, 2025, represents a firm fixed price delivery order with an ultimate completion date of September 4, 2025. This contract was competitively awarded without a set-aside designation and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania....
- The Defense Logistics Agency awarded a delivery order valued at $1,880.85 to AmerisourceBergen Drug Corp for UBRELVY 100 mg tablets (16 unit dose packs) on January 2, 2026, with a completion date of January 5, 2026. This is a firm fixed-price, non-set-aside delivery order executed under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), which carries a potential value of $999,999,999.00 and extends through December 2026. The product will be...
- The Defense Logistics Agency awarded a $5,423.70 delivery order to AmerisourceBergen Drug Corp for UBRELVY 100 mg tablets (10-unit dose packages) with a completion deadline of September 2, 2025. This competitively awarded, firm fixed-price contract represents a child delivery order under AmerisourceBergen's broader Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The work will be performed at the contractor's corporate...
- The Defense Logistics Agency awarded a delivery order valued at $22,286.82 to AmerisourceBergen Drug Corp for UBRELVY 100 mg tablets (10-count unit dose packaging) on December 16, 2025, with completion scheduled for December 17, 2025. This firm fixed-price, non-set-aside contract is part of AmerisourceBergen's broader Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The pharmaceutical distributor,...